JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

As of Dec. 4, there's no reason for it to be that confident, as Lilly took the initiative to run a direct comparison study, and the preliminary results do not appear to favor Novo Nordisk whatsoever.

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats COPENHAGEN (Reuters) - Danish businesses are concerned about a possible trade conflict with the United States over ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk (NOVOb.CO), opens ... adding that there is no clear plan for when talks will begin. Middle Eastcategory ...

I’m cautious about Novo Nordisk's stock in the short term due ... Currently, there are no FDA-approved therapies specifically for this condition. A brief reminder of the ESSENCE trial before ...

"While parts of the internet are bemused over the 'subtle' changes, as a huge brand Walmart had no reason to change its logo completely — and the design team have done a standout job in ...

Therefore, NVO looks like a no-brainer 'Strong buy' opportunity for me. Novo Nordisk is a global healthcare company headquartered in Denmark. The product's portfolio is mainly focused on diabetes ...